Kuros Biosciences Sales Soar 51% on MagnetOs Bone Graft Success

SCHLIEREN, SWITZERLAND – April 14, 2026 – Kuros Biosciences AG, a leader in next-generation bone healing technologies, today announced a remarkable start to 2026, reporting a 51% year-over-year surge in product sales for the first quarter. The impressive growth, driven almost entirely by its flagship MagnetOs bone graft product, significantly outpaces the company's own annual growth projections and signals strengthening confidence from the surgical community.

Total product sales for the three months ending March 31, 2026, reached USD 43.4 million, a substantial increase from the USD 28.8 million recorded in the same period last year. Sales from its innovative MagnetOs line accounted for nearly the entire sum, rising 51% to USD 42.9 million. This robust top-line performance translated into improved profitability, with the company posting a Group EBITDA of USD 2.9 million and an adjusted EBITDA of USD 5.7 million, representing a healthy margin of 13.1%.

Chris Fair, Chief Executive Officer of Kuros Biosciences, commented on the strong performance, stating, "Kuros is off to a strong start in 2026, building on the momentum following a record-breaking 2025. Our commercial execution remained strong in the first quarter, and we delivered USD 43.4 million in product sales, EBITDA of USD 2.9 million and adjusted EBITDA of USD 5.7 million."

The Engine of Growth: MagnetOs Technology

The driving force behind Kuros's financial success is the accelerating adoption of MagnetOs, an advanced synthetic bone graft. The product is carving out a significant position in the global orthobiologics market, a sector valued at over USD 5 billion and projected to approach USD 7 billion by the end of 2026. This market is highly competitive, featuring established giants like Medtronic and Stryker, but MagnetOs is distinguishing itself through its unique scientific foundation.

At its core is the proprietary NeedleGrip™ surface technology. This submicron surface feature is engineered to harness the body's own immune system to stimulate and guide new bone formation, a field known as osteoimmunology. Unlike some alternatives, it achieves this without the addition of cells or complex growth factors, offering a compelling safety and efficacy profile. The product’s versatility is a key selling point; it is FDA-cleared for use throughout the spine, including complex interbody procedures, as well as in the extremities and pelvis.

This broad clearance allows surgeons to use MagnetOs in a variety of applications, from traditional open spine surgeries to the rapidly growing field of minimally invasive surgery (MIS). The company noted particularly strong adoption in MIS and its extremities business, indicating that surgeons are gaining confidence in the product's handling characteristics and predictable clinical outcomes across a diverse range of procedures.

Clinical Evidence Bolsters Surgeon Confidence

Beyond strong commercial execution, Kuros is methodically building a fortress of clinical data to support MagnetOs. A recently published retrospective study in the journal Spine Open provided compelling real-world evidence of the graft's effectiveness, even in the most challenging patient populations.

The study, led by Dr. Mark Eskander, evaluated 70 patients undergoing posterior lumbar fusion and reported an overall fusion rate of 87%. Critically, 91% of these patients presented with significant comorbidities—such as heart disease, obesity, or diabetes—that typically complicate bone healing and increase the risk of surgical failure. The study also demonstrated successful fusion at early time points, with an 84.2% fusion rate observed in patients assessed less than six months after their procedure.

This real-world data complements existing high-level evidence from the MAXA trial, a Level I clinical study—the gold standard in medical research. In that trial, MagnetOs achieved a 79% fusion rate in posterolateral fusions, nearly double the 47% rate seen with autograft (the patient's own bone). The benefit was even more pronounced in active smokers, a notoriously difficult-to-treat group. To further solidify its clinical standing, Kuros confirmed that three additional Level I clinical trials are actively enrolling patients.

Fair highlighted the importance of this growing body of evidence, noting, "Our clinical story continues to strengthen, with three Level I clinical trials actively enrolling and the recently published Eskander study confirming that MagnetOs performs at early timepoints even in high-risk patient populations."

Strategic Expansion to Meet Surging Demand

To support its rapid growth trajectory, Kuros is making significant investments in its global manufacturing infrastructure. The company is executing a dual-site strategy to enhance production capacity, mitigate supply chain risks, and move closer to its key markets. A central pillar of this strategy is a new U.S. headquarters and manufacturing facility in Alpharetta, Georgia.

The 50,000-square-foot facility is on schedule to begin production in the second half of 2026 and is expected to create around 50 new jobs. This American base will be crucial for serving the large U.S. market more efficiently. Simultaneously, the company is expanding and optimizing its existing facility in Bilthoven, the Netherlands, ensuring a resilient and scalable production network capable of meeting long-term global demand.

These investments are reflected in the company's cash position, which stood at USD 15.7 million at the end of the quarter. While down from the previous quarter, the expenditure represents a deliberate deployment of capital to build the operational backbone needed for sustained, long-term growth. With a focused strategy, compelling clinical data, and a rapidly expanding operational footprint, Kuros Biosciences appears well-positioned to continue its impressive ascent in the bone healing market.